miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1

Iwagami, Yoshifumi; Eguchi, Hidetoshi; Nagano, Hiroaki; Akita, Hirofumi; Hama, Naoki; Wada, Hiroshi; Kikuchi, Kôichi; Kobayashi, Shogo; Tomokuni, Akira; Tomimaru, Yoshito; Mori, Masaki; Doki, Yuichiro

doi:10.1038/bjc.2013.320

Cited by 104 publications

(69 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…And miR-320b was reported to regulate cell-surface ICAM-1 expression on endothelial cells29. Moreover, abnormal expression of miR-320a was found in multiple malignancies including pancreatic cancer30313233 and miR-320c modulated the gemcitabine-resistance of pancreatic cancer cells through SMARCC134. The miR-320s have been shown to be dysregulated in insulin resistance, fibrosis, and pancreatic malignancies, which indicated they played pivotal roles in the development and/or complications of CP.…”

Section: Discussionmentioning

confidence: 99%

Novel blood-based microRNA biomarker panel for early diagnosis of chronic pancreatitis

Xin

Gao

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Chronic pancreatitis (CP) is an inflammatory disease characterized by progressive fibrosis of pancreas. Early diagnosis will improve the prognosis of patients. This study aimed to obtain serum miRNA biomarkers for early diagnosis of CP. In the current study, we analyzed the differentially expressed miRNAs (DEmiRs) of CP patients from Gene Expression Omnibus (GEO), and the DEmiRs in plasma of early CP patients (n = 10) from clinic by miRNA microarrays. Expression levels of DEmiRs were further tested in clinical samples including early CP patients (n = 20), late CP patients (n = 20) and healthy controls (n = 18). The primary endpoints were area under curve (AUC) and expression levels of DEmiRs. Four DEmiRs (hsa-miR-320a-d) were obtained from GEO CP, meanwhile two (hsa-miR-221 and hsa-miR-130a) were identified as distinct biomarkers of early CP by miRNA microarrays. When applied on clinical serum samples, hsa-miR-320a-d were accurate in predicting late CP, while hsa-miR-221 and hsa-miR-130a were accurate in predicting early CP with AUC of 100.0% and 87.5%. Our study indicates that miRNA expression profile is different in early and late CP. Hsa-miR-221 and hsa-miR-130a are biomarkers of early CP, and the panel of the above 6 serum miRNAs has the potential to be applied clinically for early diagnosis of CP.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel blood-based microRNA biomarker panel for early diagnosis of chronic pancreatitis

Xin

Gao

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In our study, we found that upregulated ADAM17 expression resulted in decreased E-cadherin expression and evaluated N-cadherin and Vimentin expression, suppressed ADAM17 expression resulted in increased E-cadherin expression and decreased N-cadherin and Vimentin expression, which suggested that ADAM17 could affect EMT. miRNAs bind target mRNAs at complementary sites in their 3'-untranslated regions (3'-UTRs), thereby suppressing the expression of the target gene at the posttranscriptional level [19][20][21]. Through this mechanism, miRNAs regulate a wide range of biological processes, including cell proliferation and differentiation [22], migration, apoptosis, development, and metabolism [23][24][25].…”

Section: Down-regulation Of Adam17 By Sirna Reversed the Effect Of MImentioning

confidence: 99%

Adam17, a Target of Mir-326, Promotes Emt-Induced Cells Invasion in Lung Adenocarcinoma

Cai

Wang²,

Zhang³

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: A disintegrin and metalloprotease (ADAM) 17 has been reported to be implicated in cancer cells invasion. Nevertheless, its potential role in lung adenocarcinoma has not been addressed clearly. Methods: RT-PCR and Western blot were used to detect the expression of miR-326 and ADAM17 in lung adenocarcinoma samples (n=73). miR-326 mimics and inhibitor were tansfected in human A549 and SPCA1 cell lines. The transwell assay was used to detect the cell invasive ability. The regulation mechanism was evaluated by luciferase reporter assay. The markers of (epithelial-to-mesenchymal transition) EMT were detected by using Western blot assay. Results: We found increased expression of ADAM17 in lung adenocarcinoma and cell lines. In vitro, up-regulation of ADAM17 promoted cells invasion, while silencing of ADAM17 inhibited cells invasion. Meanwhile, ADAM17 could affect the markers of EMT. Furthermore, we confirmed that ADAM17 is a target of miR-326, which is involved in EMT and cells invasion. Conclusions: These findings revealed that ADAM17, a target of miR-326, promoted EMT-induced cells invasion in lung adenocarcinoma.

show abstract

“…This study concluded that miR-142-5p is a predictive marker for gemcitabine responsivness in patients with resected pancreatic cancer. miR-320c is also found to be significantly overexpressed in gemcitabine-resistant pancreatic cancer cells suggesting its potential use as a marker for predicting clinical response [66]. Yu J et al [67] showed that patient group exhibiting high miR-200c expression had median survival of 33.5%, while it was only 11.2% in the patient group with low miR-200c expression.…”

Section: Clinical Potential Of Mirnas In Pancreatic Cancermentioning

confidence: 99%

MicroRNAs in pancreatic malignancy: Progress and promises

Srivastava¹,

Arora²,

Singh³

et al. 2014

Cancer Letters

View full text Add to dashboard Cite

Despite progress in recent years, pancreatic cancer still remains a major clinical challenge. Its incidence and mortality rates have been on consistent rise, thus underscoring the critical need for novel diagnostic, prognostic and therapeutic tools for its effective management. Recent studies have demonstrated that microRNAs (miRNAs/miRs) are deregulated in a variety of malignancies, including pancreatic cancer, and play a significant role in the initiation, progression and metastasis. Furthermore, their vital involvement in the therapeutic resistance of cancer has also been established. Hence, there has been enormous interest worldwide in investigating the roles of miRNAs in pancreatic cancer pathogenesis and exploiting their utility for clinical benefit. In this review, we summarize current knowledge on the role of miRNAs in pancreatic cancer and discuss their potential use as diagnostic and prognostic biomarkers, and as novel targets for development of effective therapeutic strategies.

show abstract

miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1

Cited by 104 publications

References 48 publications

Novel blood-based microRNA biomarker panel for early diagnosis of chronic pancreatitis

Novel blood-based microRNA biomarker panel for early diagnosis of chronic pancreatitis

Adam17, a Target of Mir-326, Promotes Emt-Induced Cells Invasion in Lung Adenocarcinoma

MicroRNAs in pancreatic malignancy: Progress and promises

Contact Info

Product

Resources

About